NCT01998971 2025-04-25A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaJanssen Research & Development, LLCPhase 1 Completed240 enrolled 2 FDA